Myeloid sarcoma is an extramedullary tumor of immature granulocytic cells. It is a rare
condition, most often associated with acute myeloid leukemia (AML), although in some rare …

Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …

Abstract On September 2, 2017, the US Food and Drug Administration approved
gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed …

Myeloid sarcoma (MS) is a rare neoplasm whose knowledge is largely based on case
reports and/or technically dated contributions. Ninety-two MSs in adulthood with clinical data …

Myeloid sarcoma is a rare disease that can present as an isolated extramedullary leukemic
tumor, concurrently with or at relapse of acute myeloid leukemia. Owing to the rarity of this …

Early clinical development in the field of targeted delivery of cytotoxic drugs to tumors was
not successful because the limitations imposed by the pharmacokinetic and …

Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal,
with no satisfactory and standard salvage chemotherapy regimen. We performed a …

Gemtuzumab ozogamicin (GO) is an immunoconjugate that binds to CD33 on the surface of
acute myeloid leukaemia (AML) blasts and, after internalisation, releases a cytotoxic drug …

Introduction: Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …

Gemtuzumab Ozogamicin (GO) is an antibody-targeted chemotherapy agent consisting of
the humanized murine CD33 antibody (clone P67. 6) to which the calicheamicin-g1 …